Therapeutic use of anti-CTLA-4 antibodies (Q38231154)

31 August 2017

title

Therapeutic use of anti-CTLA-4 antibodies (English)

1 reference

31 August 2017

1 reference

1

Christian U Blank

1 reference

31 August 2017

Alexander Enk

2

1 reference

31 August 2017

publication date

18 July 2014

1 reference

31 August 2017

published in

International Immunology

1 reference

31 August 2017

volume

27

1 reference

31 August 2017

issue

1

1 reference

31 August 2017

page(s)

3-10

1 reference

Breakthrough of the year 2013. Cancer immunotherapy

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

A new member of the immunoglobulin superfamily--CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

CTLA-4-Ig regulates tryptophan catabolism in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Modulation of tryptophan catabolism by regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Inhibition of T cell proliferation by macrophage tryptophan catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Cytotoxic T lymphocyte antigen-4-dependent down-modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T-cell-mediated suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

FoxP3+ regulatory T cells essentially contribute to peripheral CD8+ T-cell tolerance induced by steady-state dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Cutting edge: cell-extrinsic immune regulation by CTLA-4 expressed on conventional T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Properties of mouse and human IgG receptors and their contribution to disease models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Fine-tuned expression of programmed death 1 ligands in mature dendritic cells stimulated by CD40 ligand is critical for the induction of an efficient tumor specific immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Increased circulating Th17 cells after transarterial chemoembolization correlate with improved survival in stage III hepatocellular carcinoma: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Bevacizumab plus ipilimumab in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

In situ tumor ablation creates an antigen source for the generation of antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Hepatotoxicity with combination of vemurafenib and ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Immunologic correlates of the abscopal effect in a patient with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Melan-A specific CD8+ T lymphocytes after hyperthermic isolated limb perfusion: a pilot study in patients with in-transit metastases of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Biomarkers on melanoma patient T cells associated with ipilimumab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Cutting Edge: CTLA-4 on Effector T Cells Inhibits In Trans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Phase I/II trial of tremelimumab in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU076

21 January 2018

Identifiers

DOI

10.1093/INTIMM/DXU076

1 reference

31 August 2017

1 reference